COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14/03/2025 - 13:00

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through [...]

Sienna Announces March Dividend

14/03/2025 - 13:30

MARKHAM, Ontario, March 14, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

14/03/2025 - 13:30

Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) [...]

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

14/03/2025 - 13:30

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

14/03/2025 - 13:30

Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF”) Generator On track for Investigational Device Exemption (“IDE”) [...]

Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden

14/03/2025 - 13:30

Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cells Gradalis applies a novel clinically relevant approach to determine clonal tumor mutation burden/neoantigens, [...]

Hepion Pharmaceuticals Announces Reverse Stock Split

14/03/2025 - 13:30

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company [...]

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

14/03/2025 - 13:35

Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]

Healthcare Integrated Technologies Inc. Successfully Raises $10 million in Friends & Family Funding

14/03/2025 - 14:15

Knoxville, TN, March 14, 2025 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies Inc. (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the successful completion of a [...]

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

14/03/2025 - 14:30

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 14 MARCH 2025 at 15.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]

Notice to Convene Annual General Meeting 2025 - Item 6: Election of members to the Board of Directors

14/03/2025 - 15:30

Company announcement no. 4– 25 14 March 2025 Notice to Convene Annual General Meeting 2025 - Item 6: Election of members to the Board of Directors Following the publication of the Notice to Convene the Annual General [...]

Blue Antioxidant: How Prime Biome Restores Skin with 10x Retinol Strength

14/03/2025 - 15:37

ST. PETERSBURG, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a holistic daily supplement whose Blue Antioxidant is touted to be up to ten times stronger than standard retinol. For decades, retinol has [...]

Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance

14/03/2025 - 16:00

MELBOURNE, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. ( OTCPK: FITY ), formerly Consumer Automotive Finance, Inc. (OTCPK: CAFI), a dynamic leader in the sports supplement, fitness equipment, [...]

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14/03/2025 - 21:00

SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery

14/03/2025 - 21:03

TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to announce that it has successfully completed an [...]

Kestra Medical Technologies, Ltd. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option in Initial Public Offering

14/03/2025 - 21:05

KIRKLAND, Wash., March 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, announced today that the underwriters of Kestra’s initial [...]

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

14/03/2025 - 21:05

-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid [...]

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

14/03/2025 - 21:30

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, [...]

Arch Biopartners Closes Non-Brokered Private Placement

14/03/2025 - 21:30

TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed a non-brokered private placement offering of 145,000 common [...]